Marine Drugs (Nov 2015)

Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-Based Screening Assay

  • Atsuya Yamashita,
  • Yuusuke Fujimoto,
  • Mayumi Tamaki,
  • Andi Setiawan,
  • Tomohisa Tanaka,
  • Kaori Okuyama-Dobashi,
  • Hirotake Kasai,
  • Koichi Watashi,
  • Takaji Wakita,
  • Masaaki Toyama,
  • Masanori Baba,
  • Nicole J. de Voogd,
  • Shinya Maekawa,
  • Nobuyuki Enomoto,
  • Junichi Tanaka,
  • Kohji Moriishi

DOI
https://doi.org/10.3390/md13116759
Journal volume & issue
Vol. 13, no. 11
pp. 6759 – 6773

Abstract

Read online

The current treatments of chronic hepatitis B (CHB) face a limited choice of vaccine, antibody and antiviral agents. The development of additional antiviral agents is still needed for improvement of CHB therapy. In this study, we established a screening system in order to identify compounds inhibiting the core promoter activity of hepatitis B virus (HBV). We prepared 80 extracts of marine organisms from the coral reefs of Indonesia and screened them by using this system. Eventually, two extracts showed high inhibitory activity (>95%) and low cytotoxicity (66% to 77%). Solvent fractionation, column chromatography and NMR analysis revealed that 3,5-dibromo-2-(2,4-dibromophenoxy)-phenol (compound 1) and 3,4,5-tribromo-2-(2,4-dibromophenoxy)-phenol (compound 2), which are classified as polybrominated diphenyl ethers (PBDEs), were identified as anti-HBV agents in the extracts. Compounds 1 and 2 inhibited HBV core promoter activity as well as HBV production from HepG2.2.15.7 cells in a dose-dependent manner. The EC50 values of compounds 1 and 2 were 0.23 and 0.80 µM, respectively, while selectivity indexes of compound 1 and 2 were 18.2 and 12.8, respectively. These results suggest that our cell-based HBV core promoter assay system is useful to determine anti-HBV compounds, and that two PBDE compounds are expected to be candidates of lead compounds for the development of anti-HBV drugs.

Keywords